BPC-157 vs. TB-500: Research Peptide Comparison

BPC-157 and TB-500 are the two most-cited research peptides in regenerative-biology literature. They are frequently discussed together because researchers commonly study them in parallel or in combined protocols — but they are not interchangeable. The compounds differ in source protein, mechanism, half-life, and the kind of published research that supports each.

Published February 8, 2026 · Reviewed by Dr. Marina Voss, PhD (Senior Research Reviewer)

Quick comparison

	BPC-157	TB-500
Source protein	Pentadecapeptide derived from human gastric juice protein	Synthetic fragment of native Thymosin Beta-4 (residues 17–23)
Length	15 amino acids	7 amino acids
Reported half-life	Short — under 30 min plasma (subcutaneous)	Short — minutes in plasma; longer tissue retention in research models
Primary research focus	Angiogenesis modulation, NO-pathway research, gut/GI models	Actin sequestration, cardiac-protection research, fibrosis models
Key publications	Biomedicines 2021 (PMID 33391174), Regen Med 2014 (PMID 24426587)	Expert Opin Biol Ther 2007 (PMID 17192546), Ann NY Acad Sci 2012 (PMID 22737108)
Typical research dose range	10–500 µg/kg (rodent models)	1–10 mg/kg (rodent / large-animal models)
Commonly studied stacks	Often paired with TB-500 in regenerative-research protocols	Often paired with BPC-157 in regenerative-research protocols
Pre-blended SKU at BioInfinity Lab	Yes — see /buy/bpc-157-tb-500	Yes — see /buy/bpc-157-tb-500

Verdict: For researchers choosing one compound: BPC-157 dominates the GI and angiogenesis literature, while TB-500 has the deeper cardiac and actin-sequestration paper trail. For researchers running combined protocols, the pre-blended /buy/bpc-157-tb-500 vial is the simpler procurement path.

Buy BPC-157 →Buy TB-500 →

Mechanism: where the two peptides actually differ

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a protective protein endogenous to gastric juice. Published research investigates BPC-157's role in nitric-oxide pathway signaling, growth-factor expression modulation, and angiogenesis in tissue-injury research models. The Biomedicines 2021 review article (PMID 33391174) is a useful entry point for primary-literature mechanism research.

TB-500 is the synthetic fragment corresponding to amino acids 17–23 of the full 43-amino-acid Thymosin Beta-4 protein. Research literature describes its mechanism in terms of actin sequestration — Thymosin Beta-4 is one of the most abundant intracellular actin-binding proteins. The 2007 Expert Opin Biol Ther review (PMID 17192546) and the 2012 Annals NY Academy of Sciences paper (PMID 22737108) cover the relevant research-pharmacology framework.

Half-life and pharmacokinetics in published research

Both peptides are described in published research as having short plasma half-lives — typically minutes to under 30 minutes when administered subcutaneously in research models. Observed research outcomes for both compounds are generally attributed to downstream signaling effects rather than direct plasma persistence.

For researchers designing study schedules, this similarity means dosing frequency considerations are broadly comparable across the two compounds; both are commonly administered daily or every-other-day in published protocols.

Common research stacks and the pre-blended vial

Combined-protocol research using BPC-157 and TB-500 in parallel is one of the most-cited stack patterns in regenerative-biology research literature. Researchers commonly study the two together because they target complementary biological pathways — pentadecapeptide-mediated angiogenesis signaling alongside actin-binding mechanisms of Thymosin Beta-4 fragments.

BioInfinity Lab ships a pre-blended BPC-157 + TB-500 research vial for researchers running combined protocols, available at /buy/bpc-157-tb-500. Single-compound vials remain available at /buy/bpc-157 and /buy/tb-500 for researchers studying either compound in isolation.

How to choose between BPC-157 and TB-500

For researchers replicating gut, angiogenesis, or NO-pathway literature: BPC-157 is the direct match for the published compound. For researchers replicating cardiac, fibrosis, or actin-related literature: TB-500 is the direct match. For broader regenerative-research protocols where the literature uses both: the pre-blended vial removes a procurement step.

Whichever you select, BioInfinity Lab ships ≥99% HPLC-verified material with a Janoshik Analytical Certificate of Analysis referenced on the product page. Same-day shipping from New York on orders placed before 2 PM ET.

Frequently asked questions

Quick answers about the BPC-157 vs TB-500 comparison.

Are BPC-157 and TB-500 the same compound?+

No. BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein. TB-500 is a 7-amino-acid synthetic fragment of Thymosin Beta-4. They differ in length, source protein, mechanism, and the published research that supports each.

Do researchers commonly study BPC-157 and TB-500 together?+

Yes — combined-protocol research using both peptides in parallel is one of the most-cited stack patterns in regenerative-biology literature. BioInfinity Lab supplies a pre-blended vial at /buy/bpc-157-tb-500 for protocol convenience.

Which has the longer reported half-life?+

Both peptides are described in published research as having short plasma half-lives, typically minutes to under 30 minutes when administered subcutaneously. Observed outcomes for both are generally attributed to downstream signaling rather than plasma persistence.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.